Robert Radinsky
About
In The Last Decade
Robert Radinsky
126 papers receiving 10.1k citations
Hit Papers
Peers
Comparison fields: 5 of 121
- Oncology 6.3k
- Molecular Biology 4.5k
- Pulmonary and Respiratory Medicine 2.5k
- Cancer Research 2.2k
- Pathology and Forensic Medicine 1.5k
Countries citing papers authored by Robert Radinsky
This map shows the geographic impact of Robert Radinsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Radinsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Radinsky more than expected).
Fields of papers citing papers by Robert Radinsky
This network shows the impact of papers produced by Robert Radinsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Radinsky. The network helps show where Robert Radinsky may publish in the future.
Co-authorship network of co-authors of Robert Radinsky
This figure shows the co-authorship network connecting the top 25 collaborators of Robert Radinsky. A scholar is included among the top collaborators of Robert Radinsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Radinsky. Robert Radinsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 44 | |
| 2 | 116 | |
| 3 | 19 | |
| 4 | 10 | |
| 5 | 44 | |
| 6 | 12 | |
| 7 | 58 | |
| 8 | 113 | |
| 9 | Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer breakdown → | 2400 |
| 10 | Fully human Anti-HER3 monoclonal antibodies (mAbs) have unique in vitro and in vivo functional and antitumor activities versus other HER family inhibitors | 19 |
| 11 | 34 | |
| 12 | Association of somatic kRAS gene mutations and clinical outcome from a phase 2 mCRC trial of panitumumab | 1 |
| 13 | Inhibition of endocrine IGF-1 signaling in normal murine tissues and human tumor xenografts with AMG 479, a fully human anti IGF-1R monoclonal antibody | 4 |
| 14 | AMG 479, a fully human anti IGF-1 receptor monoclonal antibody, is efficacious against Ewing’s sarcoma and osteosarcoma xenografts | 6 |
| 15 | AMG 706 induces the rapid destruction of tumor microvessels in nude mice | 2 |
| 16 | 13 | |
| 17 | 76 | |
| 18 | 6 | |
| 19 | Wild-Type Human p53 and a Temperature-Sensitive Mutant Induce Fas/APO-1 Expression breakdown → | 615 |
| 20 | 94 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.